USPTO serial 79290776
HISTIDE RECODING THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 24, 2021
- Examiner
- GULIANO, ROBERT N
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with HISTIDE RECODING THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,544*
Plus Government fees of $1,950
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jacqueline M. Lesser
Jacqueline M. Lesser Ice Miller LLP1735 Market Street, Suite 3900Philadelphia, PA 19103UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for scientific use; chemicals for biotechnological product development; proteins; chemicals for the purification of proteins for in-vitro use; synthetic peptides for the manufacture of cosmetics; stem cells other than for medical or veterinary use | ACTIVE | — |
| 003 | Cosmetics; cosmetic products for skin appearance care; cosmetic preparations for skin regeneration; anti-aging skin care preparations; gels, lotions, serums, creams and ointments for cosmetic use; cosmetic preparations for hair restoration; hair lotions | ACTIVE | — |
| 005 | Pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; pharmaceutical preparations for the treatment of bone diseases, cartilaginous diseases, vascular diseases, neuronal degeneration, degeneration of tendons and ligaments, retinal degeneration, renal degeneration, degeneration of soft tissue, and diseases with abnormal cell proliferation; natural biomaterials for bone filling for medical purposes; natural biomaterials for filling cartilage for medical purposes; stem cells for medical use; surgical implants comprising living tissues; surgical dressings in the form of cloths ; surgical implants comprising living tissues grown from stem cells; synthesized peptides and polynucleotides (DNAs, RNAs) for pharmaceutical use for the treatment of tissue, whether relating to human or animal tissue, bone diseases, cartilaginous diseases, vascular diseases, neuronal degeneration, degeneration of tendons and ligaments, retinal degeneration, renal degeneration, degeneration of soft tissue, diseases with abnormal cell proliferation; nucleotide and amino acid preparations for medical use; biological tissue cultures for medical use | ACTIVE | — |
| 010 | Surgical apparatus and instruments; prostheses, namely, orthopedic prostheses, artificial joints, jaw or facial prostheses, tendon and ligament prostheses, bone prostheses, artificial bone screws, dental prostheses, vascular prostheses, heart pacemakers, artificial heart valves, breast prostheses, penile prostheses; artificial implants, namely, artificial orthopedic implants, joints, jaw or facial implants, tendon and ligament implants, skin implants, bone implants, dental implants, vascular implants, breast implants, penile implants, nerve growth implants, intraocular implants; bone substitutes for surgical use; injectors for medical use, namely, medical fluid injectors; trocars | ACTIVE | — |
| 042 | Technical consultancy in the field of scientific and industrial research; scientific, technological, industrial and quality control research and development of new products for others; scientific, technological, industrial and quality control research and development in the field of biotechnology; scientific, technological, industrial and quality control research and development for the pharmaceutical industry; scientific, technological, industrial and quality control research and development in the field of cosmetics; biological research services; chemical research services; scientific research services in the field of amino acids, proteins and cells; scientific laboratory services; chemistry services, namely, research and consulting in the field of chemistry; conducting clinical trials for others; technical project studies, namely, conducting scientific feasibility studies; engineering; chemical analysis; surveying | ACTIVE | — |
| 045 | Intellectual property licensing; online social networking services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Histide AG
- Other trademarks owned by Histide AG
- Other trademarks owned by Histide AG
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named HISTIDE RECODING THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 24, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 21, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 27, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 27, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 27, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 27, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 27, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 27, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 8, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 8, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 24, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 24, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 8, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 8, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 19, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 3, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 3, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 16, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 15, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 15, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 15, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 15, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 15, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 15, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 15, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 14, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 23, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 23, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 2, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 1, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 25, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 11, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 7, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 3, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 30, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |